1540 Ventures Fund I SEC Review: A $50 Million Target Built on a Very Limited Public Fund Track Record
THE $50 MILLION NUMBER IS A TARGET, NOT CAPITAL ALREADY RAISED
1540 Ventures Fund I, LP filed its first Form D on October 6, 2026 with a $50 million offering, but the same filing reports $0 sold, zero investors and no first sale. The fund relies on Rule 506(b) and Section 3(c)(1), expects the offering to continue for more than one year and reports no sales commissions or finder's fees. Robert King is identified as an executive alongside 1540 Ventures Fund I GP, LLC, 1540 Ventures Management, LLC and 1540 Ventures, LLC. The sponsor itself is not completely new: public materials describe 1540 Ventures as an early-stage medical-technology and life-sciences investor founded around 2023, focused on MedTech, TechBio, software-as-a-medical-device, diagnostics and women's health. But Fund I is new, and investors should be careful not to describe the $50 million figure as assets under management, commitments or fundraising success. At the filing date, none of that capital had been reported sold. Public fund databases also did not identify a matching detailed Form ADV private-fund disclosure for Fund I, so the SEC filing does not independently disclose its gross assets, administrator, auditor, custody arrangements or adviser-level regulatory structure. The contrast is significant: the manager is marketing a relatively ambitious $50 million first institutional fund while the public regulatory record still shows a day-zero vehicle. The legitimate sponsor identity reduces fraud risk, but it does not solve first-fund risk, fundraising risk or the possibility that the vehicle ultimately closes well below its stated target.
THE MOST INTERESTING CONFLICT QUESTION IS ROBERT KING'S PARALLEL VALUATION BUSINESS
A more distinctive diligence issue emerges when the manager is researched beyond the 1540 Ventures website. Robert King, 1540 Ventures' Partner and CIO, is also the founder of Five Prime Advisors, a medical-technology and life-sciences valuation and capital-structure consulting business that says it has operated since 2006. Five Prime publicly states that it performs valuations, fairness opinions and capital-structure work for venture-backed life-sciences companies and their investors. More importantly, Five Prime lists the same 1540 Broadway, Suite 1010, New York office used by 1540 Ventures, and King publicly remains associated with both organizations. None of this establishes misconduct; a venture investor having deep valuation expertise can actually improve underwriting. But the overlap creates conflict questions that Fund I investors should resolve explicitly. If Five Prime has valued, advised or provided fairness work for a company being considered by 1540 Ventures, who determines whether that company enters Fund I Can Five Prime earn consulting fees from Fund I portfolio companies Can information obtained through consulting work be used for investment decisions Who independently tests Fund I's marks if the CIO also operates a business specializing in valuing precisely the types of illiquid medical-technology securities the fund intends to own Those questions become particularly important because early-stage medtech valuations frequently depend on financing rounds, development milestones, probability-weighted regulatory outcomes and comparable transactions rather than liquid market prices. Investors should obtain the conflicts policy, related-party transaction rules and valuation-policy provisions in the LPA rather than assuming professional valuation credentials automatically produce independent valuation.
THE PUBLIC TRACK RECORD IS STILL TOO THIN TO SUPPORT A $50 MILLION FUND THESIS WITHOUT MORE EVIDENCE
1540 Ventures does have at least one independently verifiable institutional investment: it co-led AiM Medical Robotics' $8.1 million Series A with IQ Capital in 2025. That is a useful credibility point because AiM itself confirmed 1540's participation and other third parties reported the transaction. But public portfolio databases currently identify very few disclosed 1540 investments, with AiM being the clearest example, and there is no public record showing realized Fund I-style exits, audited IRR, DPI or TVPI attributable to the 1540 Ventures platform. That distinction matters because sponsor materials say the firm seeks to "mitigate" early-stage risk by investing in companies already engaged in meaningful discussions with strategic or likely exit partners. Such relationships can improve commercial validation, but discussion with a possible acquirer does not constitute an exit commitment, guaranteed acquisition or even proof that the technology will obtain regulatory clearance. AiM illustrates the point well: the company is developing an MRI-compatible neurosurgical robot and has attracted respected investors and grant support, but its own website still describes the device as investigational and not FDA approved. A portfolio concentrated in pre-seed through Series A medical technologies can face long regulatory timelines, clinical setbacks, reimbursement uncertainty, manufacturing scale-up problems and repeated financing rounds that dilute early investors. Investors should therefore ask 1540 to separate Robert King's decades of industry and valuation experience from actual returns attributable to 1540 Ventures itself and provide deal-by-deal attribution, unrealized versus realized gains, failed investments, write-downs and evidence supporting any claimed exit-pathway advantage.
FINAL RISK ASSESSMENT — EXPERIENCED MEDTECH PEOPLE, BUT A FIRST FUND WITH ZERO REPORTED CAPITAL AND REAL CONFLICT QUESTIONS
1540 Ventures Fund I passes the basic identity test: the Form D is genuine, Robert King has a long and independently visible life-sciences background, 1540 Ventures has operated publicly since roughly 2023, and its participation in the AiM Medical Robotics financing can be independently corroborated. FilingDossier found no verified evidence in the sources reviewed establishing that Fund I, 1540 Ventures or Robert King has been charged with fraud in connection with this offering. The stronger negative case is structural and measurable. Fund I was seeking $50 million but had reported $0 from zero investors when filed; no detailed matching Fund I ADV disclosure was located; the visible 1540-specific portfolio and realized exit history remain limited; and the CIO simultaneously operates a valuation consultancy serving the same medical-technology and life-sciences ecosystem from the same New York office. None of those facts disqualifies the fund, but together they make independent valuation, conflict management and track-record attribution unusually important. Before committing capital, LPs should obtain Fund I's PPM and LPA, determine the exact regulatory or exemption basis of 1540 Ventures Management, verify the auditor, administrator and bank/custody arrangements, request complete historical investment attribution, establish whether Five Prime Advisors or any other King-affiliated business may provide compensated services to portfolio companies, review how those conflicts are approved, and understand how privately held medical-device investments will be marked between financing rounds. Our assessment is therefore credible sector expertise and a verifiable emerging VC platform, but a $50 million first fund whose actual fundraising, fund-level performance and independence of valuation remain unproven at the date of its SEC filing.